Therapy Areas: Infectious Diseases
Regeneron Pharmaceuticals reveals positive initial results from Phase three clinical trial of REGEN-COV
27 January 2021 -

United States-based Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced on Tuesday positive initial results from an ongoing Phase three clinical trial assessing REGEN-COV (casirivimab and imdevimab antibody cocktail) used as a passive vaccine intended for the prevention of COVID-19 in people at high risk of infection (due to household exposure to a COVID-19 patient).

The company is jointly running the trial in collaboration with The National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH).

The firm conduced an exploratory analysis on the first around 400 assessable individuals enrolled in the trial, who were randomised to receive passive vaccination with REGEN-COV (1,200mg via subcutaneous injections) or placebo. Passive vaccination resulted in 100% prevention of symptomatic infection and around 50% lower overall rates of infection.

Regeneron is collaborating with Roche to increase global supply of REGEN-COV.

Login
Username:

Password: